UBS Group’s ADARx Pharmaceuticals, Inc. Common Stock ADRX Stock Holding History

UBS Group’s Portfolio ADRX Stock Details ADRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$18.8K	Buy	+945	New	+$18.9K	﹤0.01%	8543

Other funds holding ADRX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Landscape Capital Management Englewood, New Jersey $1.34B AUM 18.69% 1-Year Est. Return

UBS Group's ADRX Position: Q3 2026 in Review

UBS Group opened a new position in ADARx Pharmaceuticals, Inc. Common Stock (ADRX) in Q3 2026: 945 shares worth $18.8K. The stake represents ﹤0.01% of the portfolio and ranks #8543 among its holdings.

14 funds tracked by Wall St. Rank hold ADRX as of Q3 2026.

UBS Group held 945 shares of ADARx Pharmaceuticals, Inc. Common Stock worth $18.8K as of Q3 2026.
ADARx Pharmaceuticals, Inc. Common Stock was a new UBS Group position in Q3 2026.
ADARx Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #8543 holding.
14 funds tracked by Wall St. Rank held ADARx Pharmaceuticals, Inc. Common Stock as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.